|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen C, Wang L, Liao Q, Huang Y, Ye H,
Chen F, Xu L, Ye M and Duan S: Hypermethylation of EDNRB promoter
contributes to the risk of colorectal cancer. Diagn Pathol.
8:1992013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Qu YL, Wang HF, Sun ZQ, Tang Y, Han XN, Yu
XB and Liu K: Up-regulated miR-155-5p promotes cell proliferation,
invasion and metastasis in colorectal carcinoma. Int J Clin Exp
Pathol. 8:6988–6994. 2015.PubMed/NCBI
|
|
4
|
Diakos CI, Charles KA, McMillan DC and
Clarke SJ: Cancer-related inflammation and treatment effectiveness.
Lancet Oncol. 15:e493–e503. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation, and cancer. Cell. 140:883–899. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cooper K, Squires H, Carroll C,
Papaioannou D, Booth A, Logan RF, Maguire C, Hind D and Tappenden
P: Chemoprevention of colorectal cancer: Systematic review and
economic evaluation. Health Technol Assess. 14:1–206. 2010.
View Article : Google Scholar
|
|
8
|
Goh CH, Leong WQ, Chew MH, Pan YS, Tony
LK, Chew L, Tan IB, Toh HC, Tang CL, Fu WP and Chia WK:
Post-operative aspirin use and colorectal cancer-specific survival
in patients with stage I–III colorectal cancer. Anticancer Res.
34:7407–7414. 2014.PubMed/NCBI
|
|
9
|
Pagès F, Berger A, Camus M, Sanchez-Cabo
F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte
D, et al: Effector memory T cells, early metastasis, and survival
in colorectal cancer. N Engl J Med. 353:2654–2666. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mlecnik B, Tosolini M, Kirilovsky A,
Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman
WH, Pagès F and Galon J: Histopathologic-based prognostic factors
of colorectal cancers are associated with the state of the local
immune reaction. J Clin Oncol. 29:610–618. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Canna K, McMillan DC, McKee RF, McNicol
AM, Horgan PG and McArdle CS: Evaluation of a cumulative prognostic
score based on the systemic inflammatory response in patients
undergoing potentially curative surgery for colorectal cancer. Br J
Cancer. 90:1707–1709. 2004.PubMed/NCBI
|
|
12
|
Guthrie GJ, Roxburgh CS, Farhan-Alanie OM,
Horgan PG and McMillan DC: Comparison of the prognostic value of
longitudinal measurements of systemic inflammation in patients
undergoing curative resection of colorectal cancer. Br J Cancer.
109:24–28. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sabatos CA, Chakravarti S, Cha E, Schubart
A, Sánchez-Fueyo A, Zheng XX, Coyle AJ, Strom TB, Freeman GJ and
Kuchroo VK: Interaction of Tim-3 and Tim-3 ligand regulates T
helper type 1 responses and induction of peripheral tolerance. Nat
Immunol. 4:1102–1110. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Monney L, Sabatos CA, Gaglia JL, Ryu A,
Waldner H, Chernova T, Manning S, Greenfield EA, Coyle AJ, Sobel
RA, et al: Th1-specific cell surface protein Tim-3 regulates
macrophage activation and severity of an autoimmune disease.
Nature. 415:536–541. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Horlad H, Ohnishi K, Ma C, Fujiwara Y,
Niino D, Ohshima K, Jinushi M, Matsuoka M, Takeya M and Komohara Y:
TIM-3 expression in lymphoma cells predicts chemoresistance in
patients with adult T-cell leukemia/lymphoma. Oncol Lett.
12:1519–1524. 2016.PubMed/NCBI
|
|
16
|
Liu J, Zhang S, Hu Y, Yang Z, Li J, Liu X,
Deng L, Wang Y, Zhang X, Jiang T and Lu X: Targeting PD-1 and Tim-3
pathways to reverse CD8 T-cell exhaustion and enhance ex vivo
T-cell responses to autologous dendritic/tumor vaccines. J
Immunother. 39:171–180. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kuchroo VK, Umetsu DT, DeKruyff RH and
Freeman GJ: The TIM gene family: Emerging roles in immunity and
disease. Nat Rev Immunol. 3:454–462. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Piao YR, Piao LZ, Zhu LH, Jin ZH and Dong
XZ: Prognostic value of T cell immunoglobulin mucin-3 in prostate
cancer. Asian Pac J Cancer Prev. 14:3897–3901. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Piao YR, Jin ZH, Yuan KC and Jin XS:
Analysis of Tim-3 as a therapeutic target in prostate cancer.
Tumour Biol. 35:11409–11414. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zheng H, Guo X, Tian Q, Li H and Zhu Y:
Distinct role of Tim-3 in systemic lupus erythematosus and clear
cell renal cell carcinoma. Int J Clin Exp Med. 8:7029–7038.
2015.PubMed/NCBI
|
|
21
|
Ngiow SF, Teng MW and Smyth MJ: Prospects
for TIM3-targeted antitumor immunotherapy. Cancer Res.
71:6567–6571. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wiener Z, Kohalmi B, Pocza P, Jeager J,
Tolgyesi G, Toth S, Gorbe E, Papp Z and Falus A: TIM-3 is expressed
in melanoma cells and is upregulated in TGF-beta stimulated mast
cells. J Invest Dermatol. 127:906–914. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yan W, Liu X, Ma H, Zhang H, Song X, Gao
L, Liang X and Ma C: Tim-3 fosters HCC development by enhancing
TGF-β-mediated alternative activation of macrophages. Gut.
64:1593–1604. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sakuishi K, Apetoh L, Sullivan JM, Blazar
BR, Kuchroo VK and Anderson AC: Targeting Tim-3 and PD-1 pathways
to reverse T cell exhaustion and restore anti-tumor immunity. J Exp
Med. 207:2187–2194. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chono H, Saito N, Tsuda H, Shibata H,
Ageyama N, Terao K, Yasutomi Y, Mineno J and Kato I: In vivo safety
and persistence of endoribonuclease gene-transduced CD4+ T cells in
cynomolgus macaques for HIV-1 gene therapy model. PLoS One.
6:e235852011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Smolle MA, Pichler M, Haybaeck J and
Gerger A: Genetic markers of recurrence in colorectal cancer.
Pharmacogenomics. 16:1315–1328. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim MJ, Lee WY and Choe YH: Expression of
TIM-3, human β-defensin-2, and FOXP3 and correlation with disease
activity in pediatric crohn's disease with infliximab therapy. Gut
Liver. 9:370–380. 2015.PubMed/NCBI
|
|
28
|
Yang X, Liang L, Zhang XF, Jia HL, Qin Y,
Zhu XC, Gao XM, Qiao P, Zheng Y, Sheng YY, et al: MicroRNA-26a
suppresses tumor growth and metastasis of human hepatocellular
carcinoma by targeting interleukin-6-Stat3 pathway. Hepatology.
58:158–170. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yun UJ, Park SE, Jo YS, Kim J and Shin DY:
DNA damage induces the IL-6/STAT3 signaling pathway, which has
anti-senescence and growth-promoting functions in human tumors.
Cancer Lett. 323:155–160. 2012. View Article : Google Scholar : PubMed/NCBI
|
